Who is sponsoring NCT05160129?

NCT05160129 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT05160129?

Interventions in NCT05160129: Selective focal stimulation of ALIC-pathways.

What condition does NCT05160129 study?

NCT05160129 studies Obsessive Compulsive Disorder (OCD).

Is NCT05160129 still recruiting?

NCT05160129 is currently recruiting now. Last updated 12 June 2025.

Last reviewed 2025-06-12 · How we verify

NCT05160129

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder

Recruiting now NA Last updated 12 June 2025

What this trial tests

NA trial testing Selective focal stimulation of ALIC-pathways in Obsessive Compulsive Disorder (OCD) in 20 participants. Currently enrolling.

Timeline

13 August 2021

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	13 August 2021
Primary completion	31 March 2026
Estimated completion	31 March 2026
Sites	1 location across United States

Drugs / interventions tested

Selective focal stimulation of ALIC-pathways

Conditions studied

Obsessive Compulsive Disorder (OCD) — all drugs for Obsessive Compulsive Disorder (OCD) →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Obsessive Compulsive Disorder (OCD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Deep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and multiple methods of intervention. An effective DBS target for OCD is the anterior limb of the internal capsule (ALIC) brain region. On average 60% of all OCD patients have a clinically significant response to ALIC DBS. However, ALIC DBS may become even more effective with the ability to predict which specific ALIC connections in the brain need to be stimulated for each individual OCD patient. This study therefore investigates personalized stimulation to the ALIC that allows for precise modulation of brain circuits associated with individual OCD symptoms. The study aims to specify the ideal anatomical target for ALIC DBS for maximum therapeutic benefit in each patient.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991
Electrophysiological Biomarkers Reflect Target Engagement and Response Using Deep Brain Stimulation for Obsessive-Compulsive Disorder.
Van Bogaert T, Figee M, Kopell BH, Smith A, et al · · 2026 · cited 1× · PMID 41234275 · DOI 10.1016/j.bpsgos.2025.100609
Deep brain stimulation for obsessive-compulsive disorder: evolution of tractography-based targeting.
Segura-Amil A, Choi KS, Olson S, de Bruin J, et al · · 2026 · cited 1× · PMID 41172368 · DOI 10.3171/2025.6.jns243066

Verify or expand the search:

Other recruiting trials for Obsessive Compulsive Disorder (OCD)

Currently open trials in the same condition.

NCT07469358 — iCBT for Adolescents Obsessive-compulsive Dissorder · NA · active not recruiting
NCT07206212 — A Lifestyle Intervention to Reduce Cardiometabolic Risk Factors in Individuals With Obsessive-compulsive Disorder · NA · recruiting
NCT07228143 — Stepped Care Treatment for Anxiety Resilience · NA · recruiting
NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
NCT06834217 — Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder · NA · recruiting

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05160129 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 12 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05160129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing